LEARN MORE ABOUT QUTENZA®
Averitas Pharma is a revenue-generating, specialty pharmaceutical company dedicated to delivering innovative, effective, non-opioid pain management options to patients in the US.
Our company was formed in 2018, as the US commercial subsidiary of The Grünenthal Group. Grünenthal is a multinational pharmaceutical company headquartered in Germany with a presence in more than 30 countries across Europe, Latin America and the USA. For more than 70 years, Grünenthal has been a global leader in the research and development of therapeutics for pain, gout and inflammation. Now, Averitas Pharma becomes a new chapter in the company’s global growth.
Averitas means ‘from truth.’
We are committed to transparency. Averitas believes in openly sharing information and soliciting patient and physician feedback on our products and our therapeutic aims. It is such transparency and engagement that we hope leads to greater efficiency and efficacy in delivering meaningful therapies to patients.
Qutenza® is indicated for the management of neuropathic pain associated with postherpetic neuralgia.
IMPORTANT SAFETY INFORMATION:
Treatment with Qutenza® must be performed only by a healthcare provider. You should never apply or remove Qutenza® yourself.
Warnings and Precautions:
Qutenza® is not for use near eyes or mucous membranes. Do not sniff or inhale near the Qutenza® patch as this may cause you to cough or sneeze.
Do not touch the Qutenza® patch with your hands. If you touch the patch, it may cause burning and stinging; if this occurs, tell your healthcare provider.
Even though a numbing medicine is used on the skin before applying Qutenza®, some patients may still experience substantial pain during the treatment. Tell your healthcare provider if you are experiencing pain; a cool compress or medicine for the pain can be provided to help lessen your discomfort.
Qutenza® can cause serious side effects including pain and increases in blood pressure during or right after treatment. Your healthcare provider should check your blood pressure during treatment with Qutenza®.
If you have high blood pressure that is not well controlled by medicine, or who have had recent heart problems, stroke, or other vascular problems, you may be at increased risk and should discuss with your doctor whether Qutenza® is right for you.
If opioids are used to treat pain associated with the application procedure, these medicines may affect your ability to perform potentially hazardous activities such as driving or operating heavy machinery.
In clinical studies, the most common drug-related side effects of Qutenza®, which occurred in 5% or more of patients, included redness, pain, itching, or small bumps where Qutenza® was applied, and nausea. You should tell your doctor if any side effects bother you or do not go away.
Adverse Event Reporting:
Physicians, other health care providers and patients are encouraged to voluntarily report adverse events involving drugs or medical devices. To make a report you can:
In the U.S., visit www.fda.gov/medwatch, or call 1-800-FDA-1088;
For Qutenza®, you may also call 1-877-900-6479 and select option 1, or press zero on your keypad to talk to an operator to direct your call.
For more information, ask your healthcare provider or pharmacist.
Please click here for full Prescribing Information.
Carton with one patch + cleansing gel:
NDC number #10144-0928-01
Carton with two patches + cleansing gel:
NDC number #10144-0929-01
Qutenza® is a registered trademark of Averitas Pharma, Inc.